Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: Rationale, technique and early experience

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3239-3243

  Koukourakis, Michael I ^a,b   Touloupidis, Stavros ^a   Manavis, John ^a   Abatzoglou, Ioannis ^a   Sismanidou, Kiriaki ^a   Sivridis, Leonidas ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DUTH ^*  (Greece)

Author keywords

Amifostine; Hypofractionation; Prostate cancer; Radiotherapy

Indexed keywords

AMIFOSTINE; DEXAMETHASONE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONFORMAL HYPOFRACTIONATED AND ACCELERATED RADIOTHERAPY WITH CYTOPROTECTION; CONSTIPATION; CYSTITIS; DESQUAMATION; DIARRHEA; DRUG MEGADOSE; DRUG TOLERANCE; HIGH RISK POPULATION; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; PROCTITIS; PROSTATE CARCINOMA; RADIATION DOSE; RASH; SOMNOLENCE;

AGED; AMIFOSTINE; DOSE FRACTIONATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL;

EID: 6344226304     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Fertil B and Malaise E: Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Rad Oncol Biol Phys 7: 621-629, 1981.
2. Thames HD, Bentzen SM, Turesson I, Overgaard M and Van der Bogaert W: Time-dose factors in radiotherapy: a review of human data. Radiother Oncol 19: 219-235, 1990.
3. Brenner DJ and Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43: 1095-1101, 1999.
4. Fowler J, Chappell R and Ritter M: Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50: 1021-1031, 2001.
5. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD and Armour EP: Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52: 6-13, 2002.
6. Nahum AE, Movsas B, Horwitz EM, Stobbe CC and Chapman JD: Incorporating clinical measurements of hypoxia into tumor local control modelling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 57: 391-401, 2003.
7. Amdur RJ, Parsons JT, Fitzgerald LT and Million RR: The effect of overall treatment time on local control in patients with adenocarcinoma of the prostate treated with radiation therapy. Int J Radiat Oncol Biol Phys 19: 1377-1382, 1990.
8. Vesalainen S, Lipponen P, Talja M and Syrjanen K: Mitotic activity and prognosis in prostatic adenocarcinoma. Prostate 26: 80-86, 1995.
9. Tamboli P, Amin MB, Schultz DS, Linden M and Kubus J: Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma. Mod Pathol 9: 1015-1019, 1996.
10. Cher ML, Chew K, Rosenau W and Carroll PR: Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 26: 87-93, 1995.
11. Borley N, Fabrin K, Sriprasad S, Mondaini N, Thompson P, Muir G and Poulsen J: Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT. Scand J Urol Nephrol 37: 382-386, 2003.
12. Haese A, Epstein JI, Huland H and Partin AW: Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. Cancer 95: 1016-1021, 2002.
13. Meng MV and Carroll PR: Is it necessary to do staging pelvic lymph node dissection for T1c prostate cancer? Curr Urol Rep 2: 237-241, 2001.
14. Collins CD, Lloyd-Davies RW and Swan AV: Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol) 3: 127-132, 1991.
15. Livsey JE, Cowan RA, Wylie JP, Swindell R, Read G, Khoo VS and Logue JP: Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 57: 1254-1259, 2003.
16. Cassatt DR, Fazenbaker CA, Kifle G and Bachy CM: Effects of dose and schedule on the efficacy of Ethyol: Preclinical studies. Semin Oncol 30(Suppl 18): 31-39, 2003.